

# TOWARD AN EQUITABLE ACCESS TO SARS-COV-2 VACCINES FOR ALL

## WHAT IS THE GAVI COVAX AMC OFFERING LOWER INCOME COUNTRIES?

Wednesday February 17, 2021  
09.30-11.00 (Swiss time CET)

Online event



Source Pictures: Gavi.org




Schweizerische Eidgenossenschaft  
Confédération suisse  
Confederazione Svizzera  
Confederaziun svizra




SDC Health Network

# Technical reminders




## Your microphone

Please keep your mic on mute, and unmute it only when you are talking.



**If you have comments or questions** during or after a presentation or discussion, post them in the chat in writing, or raise your hand if you wish to speak using your mic.



**If you are speaking**, you can turn on your camera, internet connection permitting.



**If you can't hear or see:** close and rejoin the meeting, and close all other programs.

# Welcome



## Objectives of the webinar:

- Understand the **context** in which **the COVID-19 vaccines** are being researched & developed: what is new, what is uncertain, who are the main stakeholders, and where are the challenges?
- Get to know the **different types of COVID-19 vaccines** and understand their advantages and disadvantages in different contexts;
- Be informed about **global efforts on procurement and distribution** of COVID-19 vaccines;
- Reflect on how Swiss representations can support these efforts at the country level.

# Agenda

## First part: GAVI and ADB experts' inputs (40 minutes)

Opening, the ACT-A vaccines pillar (Gavi COVAX AMC) and SDC/Switzerland support (SDC/Carla)

**Gavi, Daniel Thommen, Senior advisor:** understanding the early context of the COVID-19 vaccine development and the current situation of the global response

**ADB, Patrick Renz, Senior advisor:** WB and Asia Pacific Vaccine Access Facility (APVAX)

## Second part: In country situation (40 minutes)

Inputs from Laos, Ethiopia, Rwanda, Mozambique – 5 minutes each

Interactive discussion

## The Access to COVID-19 Tools Accelerator (ACT-A)

CHF 70 mio

### Diagnostics

- Develop public health surveillance tools which can be used in low-resource settings
- Develop new, more reliable and affordable genetic and serological tests for highly infectious diseases
- Contribution to the **Diagnostics Partnership (FIND/GF): CHF 11 Mio**

### Therapies

- Develop safe, efficacious and affordable therapeutics which can be used in low-resource settings
- Contribution to the **COVID-19 Therapeutics Accelerator (The Wellcome Trust): CHF 19 Mio**

### Vaccines

- Accelerate the development, manufacturing and distribution of safe and affordable vaccines, which are available and can be used in low-resource settings
- Contribution to **GAVI, the Vaccine Alliance: CHF 30 Mio**
- Contribution to the **Coalition for Epidemic Preparedness Initiative CEPI: CHF 10 mio**

# Gavi 5.0 – Swiss support: CHF 10 mio

## Gavi's mission

Saving  
children's  
lives

and protecting  
people's health

by increasing  
equitable use of  
vaccines

in lower-income  
countries



# Gavi COVAX AMC – Swiss support: CHF 20 mio

**The  
COVAX  
Facility  
serves all  
countries**


The Covax AMC is an instrument for ODA-eligible countries

For ODA-eligible countries

The  
**COVAX  
AMC** –  
ODA  
*supported*

The  
COVAX  
Facility

For all countries



**Gavi**



**ADB**

**Q&A**

# Country insights

**Q&A**